Supplementation of melatonin protects human lymphocytes in vitro from the genotoxic activity of melphalan

Mutagenesis

Volumn 23, Issue 5, 2008, Pages 347-354

  Lialiaris, Theodore ^a   Lyratzopoulos, Emmanuel ^a   Papachristou, Fotini ^a   Simopoulou, Maria ^a   Mourelatos, Constantinos ^a   Nikolettos, Nikolaos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; MELPHALAN;

ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; MITOSIS INDEX; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; CELLS, CULTURED; CYTOPROTECTION; DNA DAMAGE; HUMANS; LYMPHOCYTES; MELATONIN; MELPHALAN;

EID: 50849142239     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gen020     Document Type: Article

References (80)

1. Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R. and Kroemer, G. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene, 23, 2825-2837.
2. Martin, N. M. B. (2001) DNA repair inhibition and cancer therapy. J. Photochem. Photobiol., 63, 162-170.
3. Norbuty, C. J. and Zhivotovsky, B. (2004) DNA damage-induced apoptosis. Oncogene, 23, 2797-2808.
4. Tan, D. X., Reiter, R. J., Chen, L. D., Poeggeler, B., Manchester, L. C. and Barlow-Walden, L. R. (1994) Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis, 15, 215-218.
5. Vijayalaxmi, Reiter, R. J., Herman, T. S. and Meltz, M. L. (1996) Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat. Res., 371, 221-228.
6. Tan, D. X., Poeggeler, B., Reiter, R. J., Chen, L. D., Chen, S., Manchester, L. C. and Barlow-Walden, L. R. (1993) The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett., 70, 65-71.
7. Panzer, A. and Viljoen, M. (1997) The validity of melatonin as an oncostatic agent. J. Pineal Res., 22, 184-202.
8. Witt-Enderby, P. A. and Li, P. K. (2000) Melatonin receptors and ligands. Vitam. Horm., 58, 321-354.
9. Vijayalaxmi, Reiter, R. J., Tan, D. X., Herman, T. S. and Thomas, C. R. (2004) Melatonin as a radioprotective agent: a review. Int. J. Radiat. Oncol. Biol. Phys., 59, 639-653.
10. Vijayalaxmi, Reiter, R. J. and Meltz, M. L. (1995) Melatonin protects human blood lymphocytes from radiation-induced chromosome damage. Mutat. Res., 346, 23-31.
11. De Salvia, R., Fiore, M., Aglitti, T., Festa, F., Ricordy, R. and Cozzi, R. (1999) Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage. Mutagenesis, 14, 107-112.
12. Lieberman, H. R., Waldhausser, F., Garfield, G., Lynch, H. J. and Wurtman, R. J. (1984) Effects of melatonin on human mood and performance. Brain Res., 323, 201-207.
13. Nordlund, J. J. and Lerner, A. B. (1977) The effects of oral melatonin on skin cancer and on the release of pituitary hormone. J. Clin. Endocrinol. Metab., 45, 768-774.
14. Mills, E., Wu, P., Seely, D. and Guyatt, G. (2005) Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J. Pineal Res., 39, 360-366.
15. Bizzarri, M., Cucina, A., Valente, M. G., Tagliaferri, F., Borrelli, V., Stipa, F. and Cavallaro, A. (2003) Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures. J. Surg. Res., 110, 332-337.
16. Awara, W. M., El-Gohary, M., El-Nabi, S. H. and Fadel, W. A. (1998) In vivo and in vitro evaluation of the mutagenic potential of carbamazepine: does melatonin have anti-mutagenic activity? Toxicology, 125, 45-52.
17. Liu, X., Zhaoa, J. and Zheng, R. (2003) DNA damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients. Mutat. Res., 539, 1-8.
18. Sliwinski, T., Rozej, W., Morawiec-Bajda, A., Morawiec, Z., Reiter, R. and Blasiak, J. (2007) Protective action of melatonin against oxidative DNA damage - chemical inactivation versus base-excision repair. Mutat. Res., 634, 220-227.
19. Reiter, R. J. (1996) The indoleamine melatonin as a free radical scavenger, electron donor and antioxidant. Adv. Exp. Med. Biol., 398, 307-313.
20. Pieri, C., Marra, M., Moroni, F., Recchioni, R. and Marcheselli, F. (1994) Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci., 55, 271-276.
21. Beyer, C. E., Steketee, J. D. and Saphier, D. (1998) Antioxidant properties of melatonin, an emerging mystery. Biochem. Pharmacol., 56, 1265-1272.
22. Barlow-Walden, L. R., Reiter, R. J., Pablos, M. A. M., Menendez-Pelaez, A., Chen, L. D. and Poeggeler, B. (1995) Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int., 26, 497-502.
23. Reiter, R., Tang, L., Garcia, J. J. and Munoz-Hoyos, A. (1997) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci., 60, 2255-2271.
24. Reiter, R. J., Tan, D. X., Sainz, R. M., Mayo, J. C. and Lopez-Burillo, S. (2002) Melatonin: reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol., 54, 1299-1321.
25. Ebadi, M. (2008) Alphabetical presentation of drugs. In Ebadi, M. (ed.), Desk Reference of Clinical Pharmacology. 2nd edn. CRC Press Taylor and Francis group, Boca Raton, FL, pp. 410.
26. Souliotis, V., Dimopoulos, M., Episkopou, H., Kyrtopoulos, S. and Sfikakis, P. (2006) Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. DNA Repair, 5, 972-985.
27. Dozi-Vassiliades, J., Myrtsiotis, A., Granitsas, A. and Mourelatos, D. (1985) Induction of sister-chromatid exchanges and cell-cycle delays in human lymphocytes by vitamin A alone or in combination with melphalan and caffeine. Eur. J. Cancer Clin. Oncol., 21, 1089-1092.
28. Bakopoulou, A., Mourelatos, D., Tsiftsoglou, A. S., Mioglou, E. and Garefis, P. (2008) Sister-chromatid exchange, chromosomal aberrations and delays in cell-cycle kinetics in human lymphocytes induced by dental composite resin eluates. Mutat. Res., 649, 79-90.
29. Vahrmeijer, A. L., van Dierendonck, J. H., Schutrups, J., van de Velde, C. J. H. and Mulder, G. J. (1999) Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells. Biochem. Pharmacol., 58, 655-664.
30. Ucar, M., Korkmaz, A., Reiter, R. J., Yaren, H., Oter, S., Kurt, B. and Topal, T. (2007) Melatonin alleviates lung damage induced by the chemical warfare agent nitrogen mustard. Toxicol. Lett., 173, 124-131.
31. Das, B. C. (1988) Factors that influence formation of sister chromatid exchanges in human blood lymphocytes. Crit. Rev. Toxicol., 19, 43-86.
32. Shida, C. S., Castrucci, A. M. L. and Lamy-Freund, M. T. (1994) High melatonin solubility in aqueous medium. J. Pineal Res., 16, 198-201.
33. Vijayalaxmi, Reiter, R. J., Lea1, B. Z. and Meltz, M. L. (1996) Effect of melatonin on mitotic and proliferation indices, and sister chromatid exchange in human blood lymphocytes. Mutat. Res., 351, 187-192.
34. Maskaleris, T., Lialiaris, T. and Triantaphyllidis, C. (1998) Induction of cytogenetic damage in human lymphocytes in vitro and of antineoplastic effects in Ehrlich ascites tumor cells in vivo treated by methotrexate, hypothermia and/or caffeine. Mutat. Res., 422, 229-236.
35. Lialiaris, T., Pantazaki, A., Sivridis, E. and Mourelatos, D. (1992) Chloropromazine-induced damage on nucleic acids: a combined cytogenetic and biochemical study. Mutat. Res., 265, 155-163.
36. Reiter, R. J. (1995) The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp. Gerontol., 30, 199-212.
37. Aldhous, M., Franey, C., Wright, J. and Arendt, J. (1985) Plasma concentrations of melatonin in man following oral absorption of different preparations. Br. J. Clin. Pharmacol., 19, 517-521.
38. Gonzalez, R., Sanchez, A., Ferguson, J. A., Balmer, C., Daniel, C., Cohn, A. and Robinson, W. A. (1991) Melatonin therapy of advanced human malignant melanoma. Melanoma Res., 1, 237-243.
39. Kane, M. A., Johnson, A., Nash, A. E., Boose, D., Mathai, G., Balmer, C., Yohn, J. J. and Robinson, W. A. (1994) Serum melatonin levels in melanoma patients after repeated oral administration. Melanoma Res., 4, 59-65.
40. Hu, D. N. and Roberts, J. E. (1997) Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res., 7, 27-31.
41. Hu, D. N., McCormick, S. A. and Roberts, J. E. (1998) Effects of melatonin its precursors and derivatives on the growth of cultured human uveal melanoma cells. Melanoma Res., 8, 205-210.
42. Reiter, R. J. (2004) Mechanisms of cancer inhibition by melatonin. J. Pineal Res., 37, 213-214.
43. Blask, D. E., Dauchy, R. T., Sauer, L. A. and Krause, J. A. (2004) Melatonin uptake and growth prevention in rat hepatoma 7288 CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxydecadienoic acid and the potential role of phytomelatonin. Carcinogenesis, 25, 951-960.
44. Leon-Blanco, M. M., Guerrero, J. M., Reiter, R. J., Calvo, J. R. and Pozo, D. (2003) Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J. Pineal Res., 35, 204-211.
45. Grant, K., Loizidon, M. and Taylor, I. (2003) Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer, 88, 163-166.
46. Lialiaris, T., Mourelatos, D. and Dozi-Vassiliades, J. (1988) Enhancement of cytogenetic damage by chloropromazine in human lymphocytes treated with alkylating antineoplastics and caffeine. Mutat. Res., 206, 361-365.
47. Efthimiou, M., Andrianopoulos, C., Stephanou, G., Demopoulos, N. A. and Nikolaropoulos, S. S. (2007) Aneugenic potential of the nitrogen mustard analogues melphalan, chlorambucil and p-N,N-bis(2-chloroethyl) aminophenylacetic acid in cell cultures in vitro. Mutat. Res., 617, 125-137.
48. Fousteris, M. A., Papageorgiou, A., Arsenou, E. S., Koutsourea, A. I., Karaberis, E., Mourelatos, D., Onyango, D. O. and Nikolaropoulos, S. S. (2007) Antileukemic and cytogenetic activity by triple administration of three modified steroidal derivatives of nitrogen mustards. Chemotherapy, 53, 118-126.
49. Sonoda, E., Sasaki, M. S., Morrison, C., Yamaguchi-Iwai, Y., Takata, M. and Takeda, S. (1999) Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol. Cell. Biol., 19, 5166-5169.
50. Johnson, D. R. and Jasin, M. (2000) Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J., 19, 3398-3407.
51. Cos, S., Fernandez, F. and Sanchez-Barcelo, E. J. (1996) Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci., 58, 2447-2453.
52. Cos, S., Recio, J. and Sanchez-Barcelo, E. J. (1996) Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci., 58, 811-816.
53. Blask, D. E., Wilson, S. T. and Zalatan, F. (1997) Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res., 57, 1909-1914.
54. Arendt, J. (1988) Melatonin. Clin. Endocrinol., 29, 205-229.
55. Menendez-Pelaez, A. and Reiter, R. J. (1993) Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J. Pineal Res., 15, 59-69.
56. Martín, M., Macías, M., Escames, G., León, J. and Acuña-Castroviejo, D. (2000) Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative damage. FASEB J., 14, 1677-1679.
57. Reiter, R. J., Tan, D. X. and Maldonado, M. D. (2005) Melatonin as an antioxidant: physiology versus pharmacology. J. Pineal Res., 39, 215-216.
58. Tan, D. X., Manchester, L. C., Reiter, R. J., Qi, W. B., Zhang, M., Weintraub, S. T., Cabrera, J., Sainz, R. M. and Mayo, J. C. (1999) Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim. Biophys. Acta, 1472, 206-214.
59. Huether, G., Poeggeler, B., Reimier, A. and George, A. (1992) Effect of tryptophan administration on circulating melatonin levels in chicks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci., 51, 945-953.
60. Tan, D., Manchester, L. C., Reiter, R. J., Qi, W., Hanes, M. A. and Farley, N. J. (1999) High physiological concentrations of melatonin in bile of mammals. Life Sci., 65, 2523-2529.
61. Skinner, D. C. and Malpaux, B. (1999) High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology, 140, 4399-4405.
62. Reiter, R. J., Tan, D. X., Acuna-Castroviejo, D., Burkhardt, S. and Karbownik, M. (2000) Melatonin: mechanisms and actions as an antioxidant. Curr. Top. Biophys., 24, 171-183.
63. Itoh, M. T., Ishizuka, B., Kuribayashi, Y., Amemiya, A. and Sumi, Y. (1999) Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol. Hum. Reprod., 5, 402-408.
64. Reiter, R. J. and Tan, D. X. (2003) What constitutes a physiological concentration of melatonin? J. Pineal Res., 34, 79-80.
65. Tarquini, R., Perfetto, F., Zoccolante, A., Salti, F., Piluso, A., De Leonardis, V., Lombardi, V., Guidi, G. and Tarquini, B. (1995) Serum melatonin in multiple myeloma: natural brake or epiphenomenon? Anticancer Res., 15, 2633-2637.
66. Tofilon, P., Basic, I. and Milas, L. (1985) Prediction of in vivo tumour response to chemotherapeutic agents by the in vitro SCE assay. Cancer Res., 45, 2025-2030.
67. Denn, D. F., Kendall, L. A., Marton, L. J. and Tofilon, P. (1986) Prediction of human tumour cell chemosensitivity using the SCE assay. Cancer Res., 46, 1599-1602.
68. Lissoni, P., Meregalli, S., Nosetto, L., Barni, S., Tancini, G., Fossati, V. and Maestroni, G. (1996) Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology, 53, 43-46.
69. Lissoni, P., Barni, S., Meregalli, S., Fossati, V., Cazzaniga, M., Esposti, D. and Tancini, G. (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen alone. Br. J. Cancer, 71, 854-856.
70. Koratkar, R., Vasudha, A., Ramesh, G., Padma, M. and Das, U. N. (1992) Effect of melatonin on cisplatinum induced genetic damage to the bone marrow cells of mice. Med. Sci. Res., 20, 179-180.
71. Susa, N., Ueno, S., Furukawa, Y., Ueda, J. and Sugiyama, M. (1997) Potent protective effect of melatonin on chromium (VI)-induced DNA strand breaks, cytotoxicity and lipid peroxidation in primary cultures of rat hepatocytes. Toxicol. Appl. Pharmacol., 144, 377-384.
72. Vijayalaxmi, Meltz, M. L., Reiter, R. J. and Herman, T. S. (1999) Melatonin and protection from genetic damage in blood and bone marrow: whole body irradiation studies in mice. J. Pineal Res., 27, 221-225.
73. Vijayalaxmi, Reiter, R. J. and Meltz, M. L. (1998) Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat. Res., 397, 203-208.
74. Kopjar, N., Miocić, S., Ramić, S., Milić, M. and Viculin, T. (2006) Assessment of the radioprotective effects of amifostine and melatonin on human lymphocytes irradiated with gamma-rays in vitro. Arh. Hig. Rada Toksikol., 57, 155-163.
75. Musatov, S. A., Rosenfeld, S. V., Togo, E. F., Mikheev, V. S. and Anisimov, V. N. (1997) The influence of melatonin on mutagenicity and antitumor action of cytostatic drugs in mice. Vopr. Onkol., 43, 623-627.
76. Ustundag, A. and Duydu, Y. (2007) The influence of melatonin and N-acetylcysteine in delta-aminolevulinic acid and lead induced genotoxicity in lymphocytes in vitro. Biol. Trace Elem. Res., 117, 53-64.
77. Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Conti, A. and Maestroni, G. (1994) A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer, 73, 699-701.
78. Fischer, T. W., Scholz, G., Knoll, B., Hipler, U. C. and Elsner, P. (2004) Melatonin suppresses reactive oxygen species induced by UV irradiation in leukocytes. J. Pineal Res., 37, 107-112.
79. Fischer, T. W., Scholz, G., Knoll, B., Hipler, U. C. and Elsner, P. (2001) Melatonin reduces UV-induced reactive oxygen species in a dose-dependent manner in IL-3-sitmulated leukocytes. J. Pineal Res., 31, 39-45.
80. Anisimov, V. N., Popovich, I. G., Zabezhinski, M. A., Anisimov, S. V., Vesnushkin, G. M. and Vinogradova, I. A. (2006) Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta, 1757, 573-589.